These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16923083)

  • 21. The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
    Kunsdorf-Wnuk A; Marzec-Lewenstein E; Arct-Danielak D; Musioł E; Bohatyrewicz R; Becht R
    Med Sci Monit; 2005 Aug; 11(8):CS49-55. PubMed ID: 16049385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drotrecogin alfa: a new approach in the treatment of severe sepsis.
    Vincent JL
    Expert Opin Biol Ther; 2002 Aug; 2(6):659-64. PubMed ID: 12171509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Should patients with severe sepsis be treated with activated protein C?].
    Laake JH; Bergmann JB; Riddervold F; Bjørneklett A; Aukrust P; Frøland SS
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):782-4. PubMed ID: 15039808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
    Spies C; Otter H; Zuckermann-Becker H; Kox WJ
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated protein C for severe sepsis.
    Garces K
    Issues Emerg Health Technol; 2002 Mar; (30):1-4. PubMed ID: 11985365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
    Pastores SM
    Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human activated protein C in severe sepsis.
    Mann HJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Activated protein C--recent addition to therapy of sepsis].
    Gårdlund B; Sjölin J
    Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 34. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 35. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 36. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.